DURAVYU has established safety and efficacy data from both Phase 1 and 2 trials in wet AMD and DME that demonstrate stability in vision and anatomical control with a single dose of DURAVYU. No ...
Many common conditions linked to aging develop without symptoms for years. Learn which five pose the biggest risks and the ...
Two patients developed choroidal lymphoid hyperplasia associated with vision loss after starting treatment with the GLP-1 ...
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; ...
Rare neuromuscular diseases often lack treatments because developing targeted drugs is slow, costly and risky for companies.
Gene therapy for neovascular age-related macular degeneration is linked to positive anatomical changes, but variable visual outcomes.
In an observational claims database, patients using GLP-1 receptor agonists (GLP-1RAs) had significantly lower risk of ...
PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
8d
EyePoint targets wet AMD Phase III top line data mid-year while projecting cash runway into Q4 2027
"The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President, CEO & Director Jay ...
A local retinal surgeon and ophthalmology professor will speak about age-related macular degeneration during a free webinar ...
MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results